Total submissions: 10
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory for Molecular Medicine, |
RCV000150866 | SCV000198425 | likely benign | not specified | 2013-10-31 | criteria provided, single submitter | clinical testing | Gly189Gly in Exon 03 of KCNQ1: This variant is not expected to have clinical sig nificance because it does not alter an amino acid residue, is not located within the splice consensus sequence, and has been identified in 1/1309 European chrom osomes by the ClinSeq Project (dbSNP rs200669271). |
Labcorp Genetics |
RCV000464601 | SCV000555797 | likely benign | Long QT syndrome | 2024-01-19 | criteria provided, single submitter | clinical testing | |
Illumina Laboratory Services, |
RCV001102709 | SCV001259394 | likely benign | Long QT syndrome 1 | 2017-04-27 | criteria provided, single submitter | clinical testing | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases allowed determination this variant is unlikely to cause disease. Therefore, this variant is classified as likely benign. |
Illumina Laboratory Services, |
RCV001102710 | SCV001259395 | likely benign | Jervell and Lange-Nielsen syndrome 1 | 2017-04-27 | criteria provided, single submitter | clinical testing | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases allowed determination this variant is unlikely to cause disease. Therefore, this variant is classified as likely benign. |
Illumina Laboratory Services, |
RCV001102711 | SCV001259396 | likely benign | Atrial fibrillation, familial, 3 | 2017-04-27 | criteria provided, single submitter | clinical testing | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases allowed determination this variant is unlikely to cause disease. Therefore, this variant is classified as likely benign. |
Illumina Laboratory Services, |
RCV001104619 | SCV001261497 | benign | Short QT syndrome type 2 | 2017-04-27 | criteria provided, single submitter | clinical testing | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases was too high to be consistent with this variant causing disease. Therefore, this variant is classified as benign. |
Color Diagnostics, |
RCV001842461 | SCV001353820 | likely benign | Cardiac arrhythmia | 2018-11-27 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001651012 | SCV001865265 | likely benign | not provided | 2018-10-08 | criteria provided, single submitter | clinical testing | |
Ce |
RCV001651012 | SCV002062955 | likely benign | not provided | 2024-05-01 | criteria provided, single submitter | clinical testing | KCNQ1: BP4, BP7 |
Ambry Genetics | RCV002345463 | SCV002647828 | likely benign | Cardiovascular phenotype | 2020-02-03 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |